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Background: Eosinophilic myocarditis is a rare and often under-diagnosed subtype of myocarditis with only around
30 cases published in the medical literature. In this article we present two patients with eosinophilic myocarditis
with the aim to demonstrate the often elusive nature of the disease and present the current scientific literature on
this topic.
Case presentation: A 76 years old Caucasian gentleman and a 36 years old Aboriginal gentleman both presenting
with heart failure symptoms were eventually diagnosed with eosinophilic myocarditis after extensive evaluation.
Their presentation, assessment, and medical management is explored in this article.
Conclusions: Eosinophilic myocarditis remains a rare and likely under-diagnosed subtype of myocarditis. The key
features of this disease include myocardial injury in the setting of non-contributory coronary artery disease.
Endomyocardial biopsy remains the definitive gold standard for diagnosis of noninfectious eosinophilic myocarditis.
Non-invasive cardiac imaging in the setting of peripheral eosinophilia can be strongly suggestive of eosinophilic
myocarditis with potential for earlier diagnosis. Failure to diagnose eosinophilic myocarditis and the delay of
therapy may lead to irreversible myocardial injury. Therapies for this disease have yet to be validated in large
prospective studies.
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Myocarditis refers to heart muscle inflammation secondary
to direct external antigen exposure such as viruses, bacteria,
parasites, and drugs or to autoimmune activation against
self-antigens. Traditionally the diagnosis of myocarditis was
based on the histological Dallas criteria on endomyocardial
biopsy which mandates the visualization of inflammatory
cells and myocardial necrosis on the same microscopic sec-
tion; if concomitant necrosis is not detected the diagnosis
of myocarditis is considered borderline. Given the limita-
tions of endomyocardial biopsies, in particular its low sen-
sitivity from the often patchy nature of the disease and
potential procedural risks, more recent and broader defi-
nitions of myocarditis were introduced. These encompass
a hybrid of clinical, laboratory, and imaging criteria that* Correspondence: fcordova@sbgh.mb.ca
Section of Cardiology, Department of Medicine, St Boniface Hospital and
University of Manitoba, Y3005-409 tahé avenue, R2H 2A6, Winnipeg,
Manitoba, Canada
© 2013 Rizkallah et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormay help secure the diagnosis and forgo the need for a
biopsy in all cases [1].
The prevalence of myocarditis in general is not well
established given the lack of consensus on its diagnostic
criteria in the scientific community. As such, among
unselected autopsy series, its prevalence is as high as 1
to 5% [1]. The most common causes of myocarditis
include infectious and autoimmune etiologies [1].
Eosinophilic myocarditis (EM) is a rare subtype of
myocarditis characterized by focal or diffuse myocardial
inflammation with infiltrating eosinophils and is often
associated with peripheral blood eosinophilia [2,3]. To
date there are less than 30 published case reports of EM
and include patients ranging from 2 to 83 years of age [2].
Given the rarity of this form of myocarditis, it is often
under-recognized and first discovered on postmortem
examination [4]. EM was observed in 0.5% of unselected
autopsy series and in more than 20% of explanted
hearts from heart transplant recipients secondary to
drug-induced hypersensitivity [4].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Magnetic resonance imaging with arrow depicting
subendocardial delayed enhancement in the 4 chamber axial
view.
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philic myocarditis and outline the current scientific litera-




A 76-year-old Caucasian gentleman with a history of
hypertension and asthma presents with history of sharp
and pleuritic chest pain radiating to the shoulders with
associated dyspnea with gradual deterioration of functional
status to New York heart Association (NYHA) functional
class III. Laboratory investigations revealed a normal
creatine kinase (CK), elevated troponin T at 2.74 ug/L,
C– reactive protein (CRP) at 140 mg/L (normal: 0–8),
and eosinophilia at 3.92×105/L. The initial presumptive
diagnosis was acute coronary syndrome however coron-
ary angiography revealed no significant coronary artery
disease. The patient was found to have global reduction
in left ventricular systolic function, ejection fraction
(EF) 30-35%, along with mildly impaired right ventricu-
lar dysfunction on echocardiography. In addition, an
uninfused computed tomography (CT) scan of the chest
revealed a small right pleural effusion and multiple
small centrilobar nodules in the lungs bilaterally with
upper lung zone predominance and ground glass attenu-
ation consistent with pulmonary eosinophilia. Magnetic
resonance imaging (MRI) identified mild subendocardial
delayed enhancement with a near circumferential distri-
bution raising the possibility of eosinophilic myocarditis
(Figures 1, 2). There were no suggestions of underlyingFigure 1 Magnetic resonance imaging with arrow depicting
circumferential subendocardial delayed enhancement on the
short axis view.infection and stool for ova and parasites as well as ser-
ology for trypanosome and strongyloides were negative.
A vasculitis screen including anti-neutrophil cytoplasmic
antibodies (ANCAs) was negative. There were no recently
started medications to suggest a drug induced hypersen-
sitivity reactions and physical exam and history were
negative for malignancy.
Given this presentation, a diagnosis of clinically sus-
pected eosinophilc myocarditis, idiopathic hypereosino-
philic syndrome subtype (HES) in particular, with possible
pulmonary involvement was made. The patient declined
to undergo a confirmatory endomyocardial biopsy. In
addition to the standard medical management of heart
failure he was started on oral prednisone at 60 mg per day
with 10 mg tapering doses per week to a baseline mainten-
ance dose of 10 mg per day. Unfortunately he showed little
to no recovery in cardiac function and is currently being
treated medically for his heart failure and followed as an
out-patient in the heart failure clinic.
Case 2
A 36-year-old male presents with a two-month history
of shortness of breath on exertion progressing to NYHA
class III symptoms. His history and physical examination
were otherwise unremarkable aside from this new onset
heart failure. Laboratory investigations revealed mildly
elevated white blood cell (WBC) count with mild elevation
in the absolute eosinophil count (1.7×105/L; normal range
0.0-0.4×105/L). Echocardiography demonstrated severe
biventricular dysfunction with left ventricular EF <20%
and subendocardial delayed enhancement was identified
on cardiac MRI consistent with myocarditis. Coronary
angiography was unremarkable and endomyocardial bi-
opsy demonstrated active myocarditis with intact and
degranulating interstitial eosinophils; greater then 5–8
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evidence of infection, vasculitis, malignancy, or drug
induced hypersensitivity reactions the diagnosis of idio-
pathic eosinophilic myocarditis was established. In addition
to standard heart failure treatment, 1 g/day of IV methyl-
prednisolone was initiated for three days followed by two
weeks of oral prednisone at 50 mg/day with slow taper.
The maintenance dose of steroids was unfortunately dis-
continued prematurely secondary to corticosteroid-induced
psychosis and the development of a concurrent cellulitis
and suspicion of pneumonia precluded alternative im-
munosuppressive treatment. Only mild improvement in
cardiac function was observed; the patient is currently
being treated medically for his heart failure and followed
as an out-patient at the heart failure clinic.
Discussion
When the diagnosis of myocarditis is strongly suspected
confirming the etiology as eosinophilic in nature may be
challenging short of endomyocardial biopsy given the
rarity of the disease and its vague clinical presentation.
Patients with EM may indeed present with various signs
and symptoms including fever, chills, malaise, weight
loss, acute coronary syndrome-like features, heart failure,
tachy- or brady-type arrhythmias, and sudden death [4-6].
To date there are no universally accepted guidelines for
the diagnosis of EM but as the disease becomes better rec-
ognized so will its characterization. The Japanese Circula-
tion Society Task Force Committee on Acute and Chronic
Myocarditis published helpful guidelines for the diagnosis
and treatment of EM [7]; essential diagnostic features in-
clude eosinophilia > 500/μL, cardiac symptoms, elevated
cardiac enzymes, electrocardiogram (ECG) changes, and
cardiac dysfunction on ultrasonography, especially in the
setting of unremarkable coronary angiography. Definitive
diagnosis requires an endomyocardial biopsy [8].Figure 3 Endomyocardial biopsy of a patient with eosinophilic
myocarditis (infiltrating eosinophils depicted by arrows).In EM, the eosinophils may be associated with myocar-
dial inflammation in three distinct forms [1]. The first is a
hypersensitivity reaction to a foreign antigen known as al-
lergic esosinophilic myocarditis and is often drug induced
[1]. Myocardial inflammation may also be triggered in
association with systemic eosinophilc disorders such as
Churg-Strauss. Lastly, EM may present in the form of
fulminant necrotic myocarditis of unclear etiology [1].
Clinical disorders that may result in both hypereosino-
philia and endomyocardial injury include idiopathic
hypereosinophilic syndrome, malignancies, parasitic in-
fections, vasculitic and granulomatous diseases, tropical
endomyocardial diseases, drug reactions, and transplant
rejections [9]. A paramount diagnostic feature of EM on
endomyocardial biopsy includes the detection of myo-
cardial eosinophils; these inflammatory cells are rarely
detected in normal myocardial interstitium thus their
presence is considered pathologic for EM [10]. Regard-
less of the underlying etiology of EM, whether related to
the HES or a parasitic infection, eosinophil-mediated
cardiac injury occurs in a similar fashion and ranges
from early necrosis to subsequent thrombosis and fibro-
sis [11]. On a macroscopic level this type of myocardial
injury can translate into variable degrees of focal or diffuse
structural abnormalities including systolic or diastolic
dysfunction, mural thrombi, micro-abscesses, ventricular
wall aneurysms, and rupture [10,12,13]. The sensitivity of
endomyocardial biopsy based on autopsy specimens was
estimated to be around 54% given the often patchy nature
of the disease and this is likely even lower in the beating
heart due to the technical difficulties of the biopsy proced-
ure [14]. A minimum of 5 right ventricular samples should
be obtained, however this is based on transplant rejection
data for which endomyocardial biopsy is very sensitive and
is not standardized for the detection of myocarditis [15].
Additionally, studies have shown significant interobserver
variability in the interpretation of endomyocardial biopsy
specimens in diagnosis of myocarditis [16]. Although
life-threatening complications such as right ventricular
perforation are reported to be less than 1%, the overall
complication rate including tricuspid regurgitation, oc-
cult pulmonary embolism, transient arrhythmias and
access site hematoma is as high as 6% [15].
The presence of peripheral eosinophilia may heighten
the suspicion for EM but relying solely on this laboratory
parameter to diagnose EM and judge treatment response
may be misleading. In essence, some patients with
sustained eosinophilia never develop cardiac disease
and others with biopsy confirmed EM never develop
eosinophilia throughout the course of their disease
[4,11]. The detection of eosinophil cationic protein
(ECP), one of several toxic proteins derived from the
degranulation of eosinophils, may be an adjunct to the
diagnostic potential of peripheral eosinophilia [17]. Arima
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levels of ECP in the diagnosis and treatment response of
five patients with EM showing normalization of ECP levels
with disease regression [17]. These observations sug-
gest that ECP may in part be responsible for the
pathophysiology of EM and that the number of myo-
cardial degranulated eosinophils rather than the total
number of eosinophils may be of greater diagnostic
significance [17].
Non-invasive cardiac imaging in myocarditis, such as
echocardiography, nuclear imaging with gallium67- or
indium111-labeled antimyosin antibodies, and MRI can
be useful in assessing myocardial dysfunction although
there are no specific features that help establish the
diagnosis of EM with certainty as is the case with endo-
myocardial biopsy [18]. Echocardiography is usually the
most readily available imaging modality in most institu-
tions. Common findings on 2D echocardiography include
left ventricular dysfunction in up to 69% of cases as evi-
denced by segmental wall motion abnormalities. Revers-
ible left ventricular hypertrophy can also be observed in
15% of cases while left ventricular cavity dilatation is
usually minimal or absent. In addition, only 23% will
have right ventricular involvement [18].
Nuclear imaging can be highly sensitive in detecting
evidence of myocarditis, such as myocyte necrosis
(sen 83%), and although its specificity is only moderate at
an estimated 53% it has a high negative predictive value of
92% [18]. Limitations of nuclear imaging include limited
tracer availability, poor spatial resolution, and radiation
exposure to the patients and staff [19].
Cardiac MRI is a good non-invasive diagnostic imaging
alternative, in particular when it comes to its safety, re-
producibility, and ability to accurately evaluate cardiac
anatomy and function [19]. MRI can nicely depict the
common abnormalities noted in myocarditis which in-
clude ventricular dysfunction, transient increase in wall
thickness and chamber dimensions, pericardial effusion,
and inflammatory tissue changes such as edema, capillary
leakage, hyperemia, cellular necrosis, and fibrosis [19].
Myocardial edema can be detected using T2-weighted
imaging while delayed enhancement imaging allows for
the visualization of myocardial fibrosis and inflamma-
tion. Esosinophilic myocarditis is typically characterized
by extensive myocardial hyperintensity on T-2 weighted
imaging along with subendocardial delayed enhance-
ment; mesocardial and epicardial delayed enhancement
have also been reported and the extend of delayed
enhancement is inversely proportional to LV EF [20].
Subendocardial enhancement can also be identified in
the setting of myocardial infarction which should be ex-
cluded in the evaluation of a suspect case of myocarditis.
The good diagnostic accuracy of MRI in myocarditis was
highlighted in pooled controlled trials with a sensitivityand specificity of 67 and 91% respectively along with
positive and negative predictive values of 91 and 69%
respectively [19].
The initial treatment goal in patients with EM is to
ensure hemodynamic stability. Depending on the severity
of heart failure and extent of multi-organ involvement
patients may require anywhere from intermittent diur-
esis and analgesia to full cardio-pulmonary support. In
addition, reversible and readily treatable etiologies, such
as therapy of an underlying parasitic infection or dis-
continuation of an offending drug, should be identified
and addressed as soon as possible. Given the underlying
inflammatory nature of EM, therapy with corticoste-
roids has been successfully documented in various case
reports [2-5,9]; it is important to rule out active infec-
tion on endomyocardial biopsy prior to initiation of im-
munosuppression, using viral PCR for instance, to avoid
worsening burden of disease [8]. A recent retrospective
case series by Kawano and colleagues 20112 was the
first to propose initiation and maintenance doses of
prednisolone based on disease severity; initial 1 g methyl-
prednisolone pulse dose was reserved for patients with
pre-cardiac tamponade, cardiogenic shock, and pulmonary
edema as compared to 1 mg/kg/day of prednisolone for
more stable patients; a 5-10 mg/day dose of prednisolone
was subsequently given to prevent relapse. Not all patients
with EM require corticosteroid therapy, especially if the
disease severity is very mild [2,21]. There remains little
consensus in the use, dose, or duration of corticosteroids
in the setting of EM and the need for maintenance therapy
remains to be validated in large well-designed studies [21].
A similar conundrum exists for the use of other immuno-
suppressive agents, such as azathioprine, mycophenolate,
and intravenous gammaglobulins, which have been used
in conjunction with corticosteroids in the treatment of
EM [22-24].
In our two patients, the first patient likely had a subtype
of EM known as idiopathic hypereosinophilic syndrome
(HES). This syndrome is characterized by absolute eosino-
phil count greater than 1.5×105/L lasting for more than
six months in the absence of any known cause of hypereo-
sinophilia and with evidence of multi-organ involvement
directly attributable to the eosinophilia or otherwise unex-
plained in the clinical setting [4,13,25]. In our second case
presentation, the patient did not have a sustained level of
peripheral eosinophilia during all of his medical encoun-
ters as such it remains unclear whether he had an undif-
ferentiated form EM or HES. Similar case presentations of
EM without significant levels of peripheral eosinophils
have been documented in few cases across the medical
literature [26-29]. The underlying mechanism of HES is
postulated to be a primary disorder of myelopoiesis or
an overproduction of eosinophilopoietic cytokines by lym-
phocytes [25]. The most common clinical manifestations
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features with predominant pruritis, dermatitis, asthma,
cough, dyspnea, abdominal pain, vomiting, and diarrhea
[30]. However some case series report cardiac involve-
ment in up to 40-50% of patients with HES [31]. Cortico-
steroid therapy in HES has been successfully documented
in published case reports with induced complete or partial
responses at 1 month in 85% of patients following mono-
therapy; most patients remained on maintenance doses
with a median of 10 mg prednisone equivalent daily dose
for 2 months to 20 years [4,30,32]. It remains uncertain
however why our patients failed to respond to the pro-
posed therapy. One possible explanation includes the
late initiation of therapy secondary to the elusive diag-
nosis of EM and by which time myocardial injury maybe
irreversible. In addition, sub-therapeutic initiation and
or maintenance doses, or treatment resistant fulminant
eosinophilic myocarditis may have been key factors in
the observed treatment response. In our second case pres-
entation, poor tolerance to corticosteroids and a lack of
maintenance therapy were key factor as well.Conclusion
EM remains a rare and likely under-diagnosed subtype
of myocarditis. The key features of this disease include
myocardial injury in the setting of non-contributory cor-
onary artery disease. Endomyocardial biopsy remains the
definitive gold standard for diagnosis of noninfectious
EM [8]. Non-invasive cardiac imaging in the setting of
peripheral eosinophilia can be strongly suggestive of EM
with potential for earlier diagnosis. Failure to diagnose
EM and the delay of therapy may lead to irreversible
myocardial injury. The therapies of EM have yet to be
validated in large prospective studies.Consent
Written informed consent was obtained from both patients
for publication of this case report and any accompanying
images. Copies of the written consent are available for
review by the Editor-in-Chief of this journal.
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